Trends in Breast Cancer Mortality in Sweden before and after Implementation of Mammography Screening by Haukka, Jari et al.
Trends in Breast Cancer Mortality in Sweden before and
after Implementation of Mammography Screening
Jari Haukka1*, Graham Byrnes2, Mathieu Boniol2¤, Philippe Autier2¤
1 Faculty of Medicine, Department of Public Health, University of Helsinki, Helsinki, Finland, 2 International Agency for Research on Cancer, Lyon, France
Abstract
Background: Incidence-based mortality modelling comparing the risk of breast cancer death in screened and unscreened
women in nine Swedish counties has suggested a 39% risk reduction in women 40 to 69 years old after introduction of
mammography screening in the 1980s and 1990s.
Objective: We evaluated changes in breast cancer mortality in the same nine Swedish counties using a model approach
based on official Swedish breast cancer mortality statistics, robust to effects of over-diagnosis and treatment changes. Using
mortality data from the NordCan database from 1974 until 2003, we estimated the change in breast cancer mortality before
and after introduction of mammography screening in at least the 13 years that followed screening start.
Results: Breast mortality decreased by 16% (95% CI: 9 to 22%) in women 40 to 69, and by 11% (95% CI: 2 to 20%) in women
40 to 79 years of age.
Discussion: Without individual data it is impossible to completely separate the effects of improved treatment and health
service organisation from that of screening, which would bias our results in favour of screening. There will also be some
contamination of post-screening mortality from breast cancer diagnosed prior to screening, beyond our attempts to adjust
for delayed benefit. This would bias against screening. However, our estimates from publicly available data suggest
considerably lower benefits than estimates based on comparison of screened versus non-screened women.
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Introduction
Swedish randomized trials of mammography screening (MMS)
have shown decreases in breast cancer mortality of 21%
(RR=0.79; 95% CI: 0.70–0.89) in women 40 years old and
more, after a median follow-up time of 6.5 years (range 3.0 to 18.1)
[1]. The greatest reduction of relative risk of breast cancer death,
by 32% (RR=0.68; 95% CI: 0.59–0.80), was reported in the
Two-County Trial after 20 years of follow-up [2].
Attempts to correct these results for the possible effect of
confounding by self-selection and temporal trends in breast cancer
incidence [3] suggest a reduction of 39% (RR=0.61; 95% CI:
0.55 to 0.68). However changes in incidence, i.e. increasing trend,
may be due to over-diagnosis in screened women. This is
controversial, with estimates of the rate over-diagnosis ranging
ranging from negligible [4] to 56% [5].
Mammography screening was introduced throughout Sweden
during the 1980s and 1990s. Whether results of Swedish
randomized trials were reproduced when MMS was implemented
in the general Swedish population has been addressed by several
studies and estimated reduction of breast cancer mortality has bee
estimated to be between 20% and 39% [6–11]. More recent
studies compared incidence-based breast cancer mortality before
and after the introduction of screening, i.e., breast cancer deaths in
women diagnosed with breast cancer during a pre-defined period
before and after introduction of screening were compared,
irrespective of their participation in screening. Studies using
incidence-based mortality were conducted in Darlana and
Kopparberg counties, which were part of the Two-counties Study
[12], and in nine other counties where screening was implemented
[13].
As the attendance of Swedish women for MMS in the nine
counties was high, from 70% to 88% [12,14], a reduction of
mortality of the magnitude predicted by the trials should be
discernible in the breast cancer mortality data. The objective
of this study was to assess changes in breast cancer mortality
after the introduction of MMS in the same nine Swedish
counties, using data available in the NordCan database
[15]. We used the variation of starting dates for screening by
county to separate screening effects from temporal trends in
incidence.
While it would be desirable to extend the study to the twelve
counties not included in the SOSSEG report [14], this was
impossible because of the absence of available information on
starting times and screening participation rates in any of those
counties [16].
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Methods
Region-level aggregated data on breast cancer in Swedish
women were obtained from the PC version of the NordCan
database. NORDCAN is a data base providing 30 years of data
(1974–2003) on mortality statistics from 41 major cancers in 81
regions in the Nordic countries [15]. Mortality data are obtained
from national death registration systems.
From the most recent reports (13), we selected counties (with
year of start of screening) Dalarna (1980), Ga¨vleborg (1985),
Norrbotten (1989), O¨rebro (1988), Stockholm (1990), So¨derman-
land (1990), Uppsala (1990), Va¨sternorrland (1990), and Va¨stman-
land (1990). The variation in start dates made it feasible to
separate the effect of screening from nation-wide secular trends.
Assuming that treatment improvements were not correlated with
the date of introduction of screening, it should also be possible to
separate screening and treatment effects.
Breast cancer mortality was modelled by Poisson regression,
using the following model:
ln(E Nijk)~ln(Pijk)zazbjzcf(j,l)zdi 1fage~igzki 1fcounty~kg
where
Nijk number of cases in ith age group, year j, county k
Pijk number of person-years in ith age group, year j, county k
1f g indicator function (of age group or of county)
bj start year of screening for region
f(j,l)~
0, if jv(tszl)
j-ts-l
3
, if j§(tszl) and jv(
1, if jw(tszlz3)
8><
>:
tszlz3)
l lead time
a intercept term
b log relative risk associated with secular trend
c log relative risk associated with screening
d log relative risk associated with age group i
k log relative risk associated with county k
The temporal trend coefficient b is intended to capture trends
not correlated across counties with the dates of introduction of
screening. We would expect that both changes in treatment and
increases of incidence due to risk-factor changes should be
captured by this term. In contrast, incidence changes due to
screening related over-diagnosis are expected to be correlated with
the screening start dates.
The role of the function f(j,l) is to take into account the lead time
after the start of screening, and the impact of mortality from cases
diagnosed prior to the introduction of screening. If l is the lead
time, then no mortality benefit is seen before l years after
screening, since we assume no breast cancer death can precede
clinical detection. The lead time is important to be considered
Figure 1. Breast cancer incidence and mortality in Swedish women 40 to 79 years old, 1974–2004.
doi:10.1371/journal.pone.0022422.g001
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when assessing time from diagnosis of breast cancer to death from
breast cancer, as lead time effect increases time to death when the
cancer is screen detected as compared to when the cancer is
symptomatic or clinically detected. We used a lead time of three
years in our model [3,17]. Lead time should not be confused with
the separate issue of lead-time bias, which is of concern for studies
of incidence or survival time.
It is also necessary to allow for the progressive uptake of
screening, since not all women were screened immediately, and to
account for variability in detection, timing of screening relative to
cancer development, and rate of disease progression. Therefore we
assumed that the screening benefit increased linearly from zero at l
years after the start of screening, until the full benefit was seen at
l+3 years, i.e., the lead time plus 3 years. As a check that we were
not creating the effect artificially in our model, we also applied it to
mortality from non-breast cancer. All modelling was carried out
using the R language (2.7.0) (http://www.R-project.org).
Results
Temporal trends for breast cancer incidence and mortality in
Sweden are displayed in Figure 1. Population implementation of
MMS started in 1980 in Dalarna county, and between 1985 and
1990 in the eight other counties [14]. The increase in breast
cancer incidence is mainly noticeable after 1985, in counties
included or not in the present study. In 2003, i.e., 13 years after
last year of introduction of MMS, breast cancer incidence
appeared to still be increasing (Figure 1). The secular monotone
Figure 2. Mortality rate of breast cancer in Sweden in women 40–79 years of age in nine counties, according to time of screening
start ( = 0) in each county. The continuous line is the crude mortality rate, and dashed line is mortality rate adjusted for age, secular trend, and
screening effect.
doi:10.1371/journal.pone.0022422.g002
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downward trend in breast cancer mortality since 1972 [18] was
similar in counties included in the study and in those not included.
Trends in breast cancer mortality using WHO data or NordCan
data were sufficiently similar that they cannot be distinguished
graphically, indicating similarity of data sent by the Swedish
authorities to WHO and mortality data used by the NordCan
project.
Mortality Modelling
Using the 3 year lead time estimate, reduction of breast cancer
mortality after the start of screening was 16% (RR=0.84; 95% CI:
0.78–0.91 ) in women 40 to 69 years of age, and 11% (RR=0.89;
95% CI: 0.80–0.98) in women 70 to 79 years of age. Inclusion or
exclusion of county as a categorical explanatory variable in models
did not materially change the results.
Observed and adjusted breast cancer mortality data for all nine
counties are summarized in Figure 2. A decrease in breast cancer
mortality is present about 3 years after start of screening, followed
by a stabilization of rates.
A similar modelling exercise using mortality for cancers other
than breast cancer (Table 1) showed no significant effect of time
after the start of MMS.
Discussion
According to our descriptive epidemiology analyses, in women
40 to 69 years of age, the introduction of MMS in nine Swedish
counties was associated with a 16% reduction of breast cancer
mortality.
Using an incidence-based mortality method, the Swedish
Organised Service Screening Evaluation Group (SOSSEG)
Table 1. Mortality of breast cancer (BC), and of other cancers in Swedish women from 1974 to 2003.
Age group County
Person years
(100 000) Number of BC BC deaths Other cancer deaths
(a) Age 40 to 69 Stockholm 85.87 17978 4055 15891
Dalarna 15.31 2931 648 2791
Ga¨vleborg 15.72 2593 684 3164
Norrbotten 13.80 2086 498 2299
O¨rebro 14.57 2532 675 2737
So¨dermanland 13.58 2559 638 2637
Uppsala 13.61 2428 571 2246
Va¨sternorrland 14.35 2596 669 2690
Va¨stmanland 13.07 2418 571 2543
(b) Age 40 to 79 Stockholm 105.91 23824 6190 30366
Dalarna 19.57 3978 1032 5580
Ga¨vleborg 20.04 3617 1105 6342
Norrbotten 16.89 2714 744 4195
O¨rebro 18.55 3585 1074 5423
So¨dermanland 17.03 3554 968 5047
Uppsala 16.78 3257 867 4331
Va¨sternorrland 18.22 3677 1065 5496
Va¨stmanland 16.18 3272 881 4794
doi:10.1371/journal.pone.0022422.t001
Table 2. Number of breast cancer deaths in women 40 to 69 years old in six Swedish counties according to two sources of data (3;
15).
NordCan 2008 SOSSEG 2006b
County Period
Average
population Breast cancer deaths
Average
population Breast cancer deaths % difference
Norrbotten 1976–2001 46 018 422 46 016 419 21
O¨rebro 1979–2001 48 317 512 48 502 424 217
So¨dermanland 1979–2000 45 245 466 45 445 384 218
Uppsala 1985–2001 46 241 333 45 259 250 225
Va¨sternorrland 1974–2001 47 892 632 47 633 638 1
Va¨stvmanland 1979–2001 46 110 436 46 115 352 219
All 6 counties 279 824 2 801 278 970 2 467 212
doi:10.1371/journal.pone.0022422.t002
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conducted an evaluation based on comparison between women
attending and not attending screening. Women not attending
screening may have a less healthy lifestyle, to present with more
advanced cancer and to have higher breast cancer mortality than
women attending screening. In principle, failure to take into
account the greater mortality of women not attending screening
may lead to unbalanced comparison, and overestimation of the
reduction of mortality to be expected from screening.
A companion paper to (13) using data from the same 9 counties
using Poisson regression models assessed the risk of death from
breast cancer in screened compared with unscreened women [3].
A reduction of 42% (95% CI: 38 to 47%) in breast cancer
mortality was found for screened women, after adjusting for (i)
changes in breast cancer fatality rate due to improving treatments,
(ii) for lead time–corrected follow-up time, and (iii) and for the
temporal trend of change in incidence among non screened
women before and after start of screening. The reduction was 39%
(RR=0.61; 95% CI: 0.55–0.68) after further adjustment for self-
selection.
The screening coverage in counties included in the SOSSEG
study was 78% [3], and therefore the expected reduction in
mortality for all women 50 to 69 years of age was approximately
(39% * 0.78) = 30%. If we further correct for the self-selection
effect (women attending screening contribute slightly less than
their share of deaths), this decreases by a fraction 39/42 to 28%.
Our estimate of 16% should be compared to this.
The reasons for the substantial discrepancy between our
estimate and those of the Swedish group [3] follow from
differences in model assumptions, model parameters, adjustment
procedures and possibly data. The Swedish group modelled the
risk of breast cancer death associated with being screened, whereas
we modelled breast cancer mortality rates of the entire population
eligible for screening.
One difference in approach is the correction for the change in
incidence after and before the start of screening. This was done
explicitly by the Swedish Group [3], which could lead to an over-
estimate of the benefit of screening if there is screening-related
over-diagnosis. There is relatively strong evidence that breast
cancer incidence as much increased after screening introduction,
which has lead to recognize overdiagnosis as being a major side
effect of screening [19–23]. Our model seeks to distinguish
temporal effects on mortality (b in our model) from screening by
virtue of the varying dates of screening introduction by county. We
felt this approach was preferable since incidence was already
increasing faster than mortality [18] and it allows partial
correction for both changes of incidence and treatment-related
improvements in survival. Furthermore, in Sweden, breast
mortality stabilized and started to decrease well before mammog-
raphy screening programmes existed (see Figure 1).
Differences in data used by studies could be another possible
reason for the difference in results. Breast cancer mortality data for
Sweden in NordCan database are similar to those present in the
WHO mortality database. We could compare numbers of breast
cancer deaths in our and in the SOSSEG study (14) for the same
period of time and age range for six counties (Table 2). On
average, death counts used in the SOSSEG study [3] were 12%
lower than that from the NordCan database. We are not aware of
changes in death certification process in Sweden after 1980 likely
to explain this discrepancy.
It remains also to determine if the reduction in breast cancer
mortality we found after the start of screening was due to
mammography screening itself, or to generalization of efficient
cancer treatment that took place end of the 1980s, or to greater
breast awareness and improved management of breast cancer
patients induced by the screening programme (e.g., because of
reorganization of clinical work or greater access to efficient
treatments). The influence of treatment and of awareness in
mortality reductions has been stressed by model approaches
showing the key role of treatments [24]. In addition, in many high
income countries, mortality reductions started well before or
around the year screening started and these reductions were
mainly observed in women less than 50 years of age even in
countries where screening of young women is rare [25]. Our
model attempts to correct for log-linear temporal trends in
mortality, whether due to treatment or risk-factor induced changes
in incidence. However it will not effectively capture step changes
correlated to screening as would be expected from the above
factors. This question has been addressed by the study by Kalager
et. al. of mammographic screening in Norway (20), by comparing
both screened and unscreened women to historic controls. They
concluded that two-thirds of the reduction in mortality was likely
due to non-screening factors, with screening itself generating a
10% (95% CI 24 to 24%) reduction in mortality. We would echo
their conclusion: that the benefit of mammographic screening in
isolation is modest, and that the larger estimates of benefit may be
due to improved integration of treatment associated with
screening.
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